Back

Attenuation of the CpG Island Methylator Phenotype and lack of WNT signaling activation restrains Kras mutant intestinal neoplasia

Fennell, L. J.; Tria, S.; Liu, C.; Kane, A.; McKeone, D.; Borowsky, J.; Chai, L.; Randall-demllo, S.; Bond, C. E.; Leggett, B.; Whitehall, V. L.

2023-12-23 cancer biology
10.1101/2023.12.21.572936 bioRxiv
Show abstract

BackgroundSerrated neoplasia accounts for [~]25% of colorectal cancer. These cancers arise from serrated precursor lesions. Hyperplastic polyps initiated by either BRAF or KRAS mutation activating MAPK signalling are common, but premalignant sessile serrated lesions with KRAS mutation are rare. Here, we model Kras and Braf mutant neoplasia in vivo to compare histological, gene expression and DNA methylation manifestations associated with activation of these oncogenes. MethodsWe employ cre-recombinase dependent BrafV637 and KrasG12D murine models, and cross animals with those bearing the Villin-CreERT2 transgene to direct temporospatial activation of these oncogenes to the murine intestine. We examine histology, and genome-scale DNA methylation and gene expression via reduced representation bisulphite sequencing and RNA-Seq, respectively. We performed differential gene expression, methylation and pathways analysis to identify oncogene specific alterations. ResultsProlonged exposure to oncogenic Braf is associated with a time-dependent accumulation of murine serrated precursors (P=3x10-10) and advanced murine serrated lesions and invasive cancer (8x10- 8). Kras mutant animals acquire fewer precursor lesions (P=0.06) and have a significantly lower probability of developing advanced serrated lesions (P=0.004). Braf and Kras mutant animals develop pronounced hyperplasia, however the severity is significantly less in Kras mutant animals. Kras mutant advanced serrated lesions rarely develop aberrant WNT signaling activation (1/23). Gene expression profiling showed divergent transcriptomic profiles between Braf and Kras mutant intestines, with the former overexpressing genes associated with immune and inflammatory signaling. Deconvolution analysis revealed a comparably higher macrophage infiltrate (P=0.025) and upregulation of M1 macrophage gene sets in the Braf mutant intestine (P=0.0008), contributing to chronic inflammatory signalling. Both Kras and Braf mutations lead to accumulation of substantial temporal DNA methylation alterations, however a subset of CpG sites (1,306) show an attenuated rate of DNA methylation accumulation in the Kras mutant intestine compared with Braf mutant animals. ConclusionsIn this study, we show that Kras mutation can induce serrated intestinal neoplasia, however the latency period and penetrance is significantly lower when compared with Braf mutation. Aberrant WNT signalling is common in lesions arising in the context of Braf mutation, but rare in Kras mutant neoplasms. We show marked transcriptomic disparities between these models, with a tendency for the Braf mutant intestine to upregulate immunological processes. Our DNA methylation analysis reveals an attenuated CIMP-like phenotype that is specific to the Kras mutant intestine, consistent with our previous works in humans. These data have significant implications for our understanding of how MAPK-induced neoplasia develops within the intestine. SynopsisBRAF and KRAS mutant hyperplastic polyps have disparate malignant potential and the reason for this is unclear given both oncogenes activate MAPK signalling. We show that the DNA methylation alterations that follow Kras mutation are attenuated and that hyperactivation of WNT signaling is rare, providing a molecular mechanism that restrains malignant transformation.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.1%
28.0%
2
Clinical Epigenetics
53 papers in training set
Top 0.1%
10.2%
3
Cancers
200 papers in training set
Top 0.5%
8.5%
4
Gut
36 papers in training set
Top 0.1%
4.9%
50% of probability mass above
5
Gastroenterology
40 papers in training set
Top 0.6%
3.1%
6
PLOS ONE
4510 papers in training set
Top 45%
2.6%
7
Scientific Reports
3102 papers in training set
Top 50%
2.1%
8
BMC Cancer
52 papers in training set
Top 1%
1.8%
9
British Journal of Cancer
42 papers in training set
Top 0.8%
1.7%
10
The Journal of Pathology
22 papers in training set
Top 0.1%
1.7%
11
npj Precision Oncology
48 papers in training set
Top 0.5%
1.7%
12
JCI Insight
241 papers in training set
Top 3%
1.7%
13
Cancer Research
116 papers in training set
Top 2%
1.5%
14
Molecular Oncology
50 papers in training set
Top 0.5%
1.3%
15
eLife
5422 papers in training set
Top 47%
1.3%
16
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.4%
1.2%
17
Frontiers in Oncology
95 papers in training set
Top 3%
1.2%
18
Nature Communications
4913 papers in training set
Top 57%
1.1%
19
Frontiers in Immunology
586 papers in training set
Top 6%
1.1%
20
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.0%
21
Molecular Cancer Research
42 papers in training set
Top 0.7%
0.8%
22
Oncogene
76 papers in training set
Top 2%
0.8%
23
PLOS Genetics
756 papers in training set
Top 15%
0.8%
24
Cell Communication and Signaling
35 papers in training set
Top 1%
0.8%
25
Neoplasia
22 papers in training set
Top 0.8%
0.7%
26
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
27
BMC Medicine
163 papers in training set
Top 8%
0.7%
28
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 2%
0.5%
29
Aging
69 papers in training set
Top 4%
0.5%
30
Biology Open
130 papers in training set
Top 4%
0.5%